Monogram Orthopaedics (MGRM) Stock Price, News & Analysis

Company Overview

Monogram Orthopaedics, traded on Nasdaq under the ticker MGRM, is a commercial-stage medical device company focused on developing and delivering personalized knee replacement solutions. The company’s mission centers on improving patient outcomes in knee arthroplasty by leveraging advanced design and manufacturing methods to tailor implants and instrumentation to each individual’s unique anatomy.

At the core of Monogram’s offering is the Monogram Knee System, which combines proprietary imaging software with additive manufacturing techniques to produce patient-specific implants and surgical instruments. Preoperative MRI or CT scans are used to create a three-dimensional model of the patient’s knee, allowing the system to optimize implant geometry, alignment guides, and cutting blocks. This customized approach aims to enhance implant fit, reduce surgical times, and potentially improve post-operative function and comfort.

Founded in 2018 and headquartered in Menlo Park, California, Monogram Orthopaedics has secured FDA 510(k) clearance for its partial knee replacement system and completed its first commercial cases in leading U.S. orthopedic centers. The company continues to expand its commercial footprint across the United States, with plans to pursue additional regulatory approvals and market entry in select international regions.

Key Stats

• Today's Range: $5.68 to $5.79
• 50-Day Range: $2.91 to $6.01
• 52-Week Range: $1.92 to $6.02
• Volume: 76,582 shs
• Average Volume: 94,689 shs
• Market Capitalization: $233.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.40
• Consensus Rating: Strong Buy

Monogram Orthopaedics Stock Analysis - MarketRank™

Monogram Orthopaedics scored higher than 38% of companies evaluated by MarketBeat, and ranked 751st out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Monogram Orthopaedics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Downside Risk

Monogram Orthopaedics has a consensus price target of $5.40, representing about 6.1% downside from its current price of $5.75.

Amount of Analyst Coverage

Monogram Orthopaedics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Monogram Orthopaedics are expected to grow in the coming year, from ($0.49) to ($0.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Monogram Orthopaedics is -11.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Monogram Orthopaedics is -11.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Monogram Orthopaedics has a P/B Ratio of 13.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.84% of the float of Monogram Orthopaedics has been sold short.

Short Interest Ratio / Days to Cover

Monogram Orthopaedics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Monogram Orthopaedics has recently decreased by 26.07%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Monogram Orthopaedics does not currently pay a dividend.

Dividend Growth

Monogram Orthopaedics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.84% of the float of Monogram Orthopaedics has been sold short.

Short Interest Ratio / Days to Cover

Monogram Orthopaedics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Monogram Orthopaedics has recently decreased by 26.07%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.45

News Sentiment

Monogram Orthopaedics has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Monogram Orthopaedics this week, compared to 1 article on an average week.

Search Interest

2 people have searched for MGRM on MarketBeat in the last 30 days.

MarketBeat Follows

Only 5 people have added Monogram Orthopaedics to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Monogram Orthopaedics insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.10% of the stock of Monogram Orthopaedics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.45% of the stock of Monogram Orthopaedics is held by institutions.

MGRM Stock Analysis - Frequently Asked Questions

How have MGRM shares performed this year?

Monogram Orthopaedics' stock was trading at $2.37 at the beginning of the year. Since then, MGRM stock has increased by 142.6% and is now trading at $5.75.

How were Monogram Orthopaedics' earnings last quarter?

Monogram Orthopaedics Inc. (NASDAQ:MGRM) posted its earnings results on Friday, August, 15th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.05.

When did Monogram Orthopaedics IPO?

Monogram Orthopaedics (MGRM) raised $17 million in an IPO on Thursday, May 18th 2023. The company issued 2,374,641 shares at a price of $7.25 per share.

Who are Monogram Orthopaedics' major shareholders?

Monogram Orthopaedics' top institutional investors include Orion Porfolio Solutions LLC (0.03%), Jane Street Group LLC (0.04%) and Crestwood Advisors Group LLC (0.03%).

How do I buy shares of Monogram Orthopaedics?

Shares of MGRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Monogram Orthopaedics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Monogram Orthopaedics investors own include Faraday Future Intelligent Electric (FFIE), Plug Power (PLUG), AMC Entertainment (AMC), CXApp (CXAI), Draganfly (DPRO) and

Company Calendar

• Last Earnings: 8/15/2025
• Today: 9/14/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:MGRM
• CIK: 1769759
• Web: www.monogramorthopedics.com
• Phone: 512-399-2656
• Fax: N/A
• Employees: 28
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Monogram Orthopaedics: $5.40
• High Price Target: $5.40
• Low Price Target: $5.40
• Potential Upside/Downside: -6.1%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.33 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -126.82%
• Return on Assets: -96.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.16
• Quick Ratio: 2.16

Sales & Book Value

• Annual Sales: $370 thousand
• Price / Sales: 631.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.42 per share
• Price / Book: 13.69

Miscellaneous

• Outstanding Shares: 40,630,000
• Free Float: 29,214,000
• Market Cap: $233.62 million
• Optionable: Not Optionable
• Beta: 0.69